Replies to post #120027 on Biotech Values

[biomaven0]

I wouldn't say switchover back and forth is big concern.

The theoretical issue is that you somehow engender cross-immunogenicity when switching back and forth between multiple different generics. With complex proteins that are all a bit different from each other it is a potential concern.

Peter